Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data relating to the Prosigna Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 taking place May 5-8.

“New data accepted for presentation at this year’s ESMO Breast Cancer Congress provide further evidence for the importance of genomic testing in breast cancer, particularly to help physicians and patients make better informed treatment decisions based on the unique biology of individual patients’ tumors,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We believe such data strengthen the backdrop for our Prosigna Breast Cancer Gene Signature Assay, and greatly appreciate the breast cancer experts who led and participated in these studies.”

Following are details of the Prosigna-related posters accepted for presentation at the ESMO Breast Cancer Virtual Congress. These abstracts are available to meeting registrants on demand:

Title:		Influence of PAM50 on therapeutic decisions in patients with early-stage Luminal Breast Cancer in a single centre
Poster:		62P
First Author:		Alejandro Olivares-Hernandez, M.D., M.Sc., IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
Title:		Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European Breast Cancer clinicians - The PROCURE project
Poster:		24P
First Author:		Giuseppe Curigliano, M.D., Ph.D., IEO - Istituto Europeo di Oncologia, Milan, Italy

The first poster will present findings from a prospective study conducted at the University Hospital of Salamanca (Spain), evaluating the influence of the PAM50 gene signature, the foundation of the Prosigna assay, on therapeutic decision-making for 143 patients with early-stage breast cancer.